A nuclear manufacturing technician uses a manipulator arm to work samples in a hot cell.

University of Missouri initiative to boost radioisotope production

Expansion plans will scale up production at the University of Missouri Research Reactor, the only U.S. supplier of the lutetium-177 radioisotope.
University of Missouri President Mun Choi delivers his State of the University speech

NextGen MURR featured in State of the University Address

University of Missouri President Mun Choi gave his 2024 State of the University Address for Mizzou on Sept. 25.
Governor Mike Parson presents the Hawthorn Foundation Project of the Year Award to UM System President Mun Choi and other university leaders.

University of Missouri Research Reactor (MURR) wins Hawthorn Foundation Project of the Year Award

This recognition underscores Mizzou’s pivotal role in positioning Missouri as a leader in nuclear science and technology. Sept. 5, 2024 — The University of Missouri Research Reactor (MURR) has been named the 2024 Hawthorn Foundation Project of the Year Award for its groundbreaking work and significant contributions to scientific research, innovation and economic development in Missouri. Read More…
Headshot of Michael Hoehn II, inaugural program director for NextGen MURR. He is a white man with dark, short hair wearing a dark brown suit.

Michael Hoehn II named inaugural NextGen MURR program director

June 4, 2024 — The University of Missouri has selected Michael Hoehn II as the inaugural program director for NextGen MURR.
Graphic shows microscopic yttrium-90 radioisotopes in a human liver.

Innovative yttrium-90 transforms liver cancer treatment

March 28, 2024 — Liver cancer is one of the deadliest forms of the disease, with an estimated 71 percent mortality rate for patients in the U.S. diagnosed with primary liver and intrahepatic bile duct cancer.
Carolyn Anderson, left, and graduate student Ejike Iweha discuss research on terbium-161 in the Anderson lab at the University of Missouri's Molecular Imaging and Theranostics Center.

Adding a radioisotope to the toolkit for saving lives

Feb. 27, 2024 — Ground-breaking innovation provides patients around the world with access to a lifesaving toolbox of vital pharmaceutical ingredients called radioisotopes produced at MURR.
Dec. 13, 2023 — University of Missouri Health Care has initiated its first treatment using an FDA-approved targeted radioactive medicine for advanced metastatic prostate cancer. Photo shows vial of Pluvicto®, which is the brand name for the radiopharmaceutical.

MU Health Care pilots treatment for prostate cancer

Dec. 13, 2023 — University of Missouri Health Care has initiated its first treatment using an FDA-approved targeted radioactive medicine for advanced metastatic prostate cancer.
Chris McCarty, a University of Missouri Research Reactor (MURR) shipping technician, prepares a weekly delivery of no-carrier-added lutetium-177 (Lu-177) to Novartis for use in cancer treatments. MURR is the sole producer in the United States of NCA Lu-177, the active ingredient in two targeted radioligand therapies commercially produced by Novartis for cancer treatment.

MURR ships radioisotope for cancer treatment

Dec. 6, 2023 — The University of Missouri Research Reactor (MURR) recently completed its first commercial shipment of no-carrier-added lutetium-177 for human use and is providing weekly deliveries to Novartis for use in cancer treatments.
University of Missouri leaders and partners perform a ceremonial dirt turn during the groundbreaking ceremony for MURR West.

MU breaks ground on MURR addition

Oct. 2, 2023 — The University of Missouri hosted a groundbreaking ceremony today for a 47,000-square-foot addition to the MU Research Reactor (MURR) facility.
Photo of the University of Missouri columns with Jesse Hall in background.

Matt Sanford named executive director for MURR 

July 13, 2023 — University of Missouri President Mun Choi has announced Matt Sanford as executive director for the University of Missouri’s Research Reactor (MURR).